Citius Oncology, Inc. (CTOR) vs Pulmonx Corporation (LUNG)
A side-by-side comparison of Citius Oncology, Inc. and Pulmonx Corporation across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CTOR
Citius Oncology, Inc.
$0.87HealthcareDelayed quote: Oct 6, 2026, 11:10 AM EDT
LUNG
Pulmonx Corporation
$1.90HealthcareDelayed quote: Oct 6, 2026, 11:10 AM EDT
Total return — CTOR vs LUNG
growth of $100 · dividends reinvested · last 2yCTOR -92.4% (-72.4%/yr)LUNG -77.7% (-52.7%/yr)LUNG compounded faster over this window
CTOR LUNG
CTOR vs LUNG: by the numbers
- •CTOR is the larger company ($81M vs $80M market cap).
- •Both run net losses; LUNG's is the smaller (-55.03% vs -648.32% net margin).
Metrics side by side
Valuation
| Metric | CTOR | LUNG |
|---|---|---|
| Forward P/E | 8.70 | N/A |
| P/S ratio | 11.39 | 0.92 |
| P/B ratio | 2.00 | 2.04 |
Profitability
| Metric | CTOR | LUNG |
|---|---|---|
| Gross margin | 0.00% | 77.06% |
| Operating margin | 0.00% | -52.96% |
| Net margin | -648.32% | -55.03% |
| ROE | -114.06% | -122.76% |
| ROIC | -88.72% | -48.39% |
Growth (annualized)
| Metric | CTOR | LUNG |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 15.86% |
| Total return CAGR (5Y) | N/A | -45.30% |
Go deeper
Dig into the metrics
Citius Oncology ROEPulmonx ROECitius Oncology operating marginPulmonx operating marginCitius Oncology revenue growthPulmonx revenue growthCitius Oncology free cash flowPulmonx free cash flow
Citius Oncology & Pulmonx appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.